In conclusion, the presented data describe a simple methodology based on the daily use of the CellSearch platform for the identification of KRAS mutational status of CTCs from patients with metastatic colorectal cancer and provide a rationale for considering re-assessment of KRAS mutational status in CTCs in order to better predict response to anti-EGFR therapy. Here, EGFR is linked to metastatic colorectal cancer.